31 August 2017
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Redx to present new scientific data at ESMO 2017
Redx Pharma will present a poster on their planned first-in-human clinical trial for RXC004 at the European Society for Medical Oncology (ESMO) Annual Meeting, September 8-12, 2017, in Madrid.
Session Date & Time |
September 9, 2017, 13:15 AM -14:15 GMT+1h |
Session Title |
GASTROINTESTINAL TUMOURS, COLORECTAL |
Presentation Title |
Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening |
Session Location |
Hall 8 |
Abstract # |
692P |
First author |
Matilda Bingham |
Abstract online |
https://cslide.ctimeetingtech.com/library/esmo/browse/search/2iw4#2Bb5o02mE |
Iain Ross, Chairman, commented:
'We're delighted to present new scientific data on our most advanced program, the Porcupine inhibitor RXC004 as it moves closer to the clinic. We have a strong portfolio of research assets and continue to look for novel opportunities in several therapeutic classes in oncology and immunology.'
For further information, please contact:
Redx Pharma Plc (in administration) |
|
Contact for the Joint Administrators: Chris French James Rossiter
|
T: + 44 203 005 4000 |
Cantor Fitzgerald Europe (Nomad & Broker) |
T: +44 20 7894 7000 |
Phil Davies |
|
|
|
WG Partners LLP (Joint Broker) |
T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
About Redx Pharma Plc (in administration)
Company website: redxpharma.com
Jason Baker and Miles Needham have been appointed as joint administrators of Redx Pharma plc (in administration). The company's affairs, business and property are being managed by the joint administrators.
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.